KLRA — Kailera Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks
Advisory: Research alert on Kailera Therapeutics withdrawn
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut (updated)
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
Biotech firm Odyssey raises $279 million in upsized US IPO (updated)
Biotech firm Odyssey targets $810 million valuation in US IPO (updated)
Obesity drug developer Kailera pops in Nasdaq debut after $625 million IPO
Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up (updated)
Weight-loss drugs developer Kailera surges 62.5% in Nasdaq debut
NASDAQ RESUMED AT 01:25 PM
Obesity drug developer Kailera on track for Nasdaq debut above offer price
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Kailera Therapeutics Announces Pricing Of Initial Public Offering